Glioblastoma with deep supratentorial extension is associated with a worse overall survival

Glioblastoma (GBM) is the most common primary brain tumor in adults, with a dismal median survival time of 15 months, and a 5-year survival rate of less than 2% [1]. Despite advances in genetic biomarker testing that is used to guide post-operative adjuvant chemoradiation treatment, there has been little progress in preoperative prognostication for patients with GBM [2]. While GBM follows a relatively standard clinical course in that it is a rapidly growing tumor that is often precipitously fatal, its location within different brain regions has been shown to portend variable outcomes.